The disruption of endothelial continuity is initiated by a tumor-derived cANGPTL4 through direct interaction with integrin α5β1, VE-cadherin, and Claudin-5 in a temporally sequential manner [53]. The gene discussed is CLDN5; the disease is neoplasm.